Eculizumab

Eculizumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.

Eculizumab was granted FDA approval on 16 March 2007.

Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. Eculizumab has a long duration of action. Patients taking this medication should be vaccinated against Neisseria meningiditis as serious meningococcal infections have occurred in the past.

Eculizumab
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Eculizumab
Availability	Prescription only
Generic	Eculizumab
Eculizumab Other Names	Eculizumab
Related Drugs	pyridostigmine, neostigmine, Mestinon, Soliris, Vyvgart, Ultomiris, ravulizumab, Uplizna, Empaveli, Enspryng
Weight	10mg/ml,
Type	Intravenous Solution, Intravenous
Weight	148000.0 Da
Protein binding	Though protein binding data is scarce, eculizumab is unlikely to be protein bound as it is a monoclonal antibody.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Eculizumab is a recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD).

Eculizumab is also used to associated treatment for these conditions: Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Haemoglobinuria (PNH)

How Eculizumab works

Eculizumab is a monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Inhibition of this complex prevents complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobunuria, complement mediated microangiopathy in atypical hemolytic uremic syndrome, and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder.

Toxicity

Overdoses of eculizumab are unlikely as it is administered under specialist supervision. In case of overdose, contact local poison control.

Food Interaction

No interactions found.

Eculizumab Disease Interaction

Major: meningococcal infections, infections, PMLModerate: thrombotic microangiopathy, vaccination

Volume of Distribution

The volume of distribution of eculizumab is 5-8L.

Elimination Route

Eculizumab is administered by intravenous infusion so the bioavailability is 100%. This drug reaches a C_max of 194±76µg/mL and C_trough of 97±60µg/mL. The AUC was calculated to be 24,467.6µg*h/mL.

Half Life

The half life of eculizumab is 270-375h or 272±82h.

Clearance

Pharmacokinetic properties in healthy patients have not been determined. In patients with rhematoid arthritis, there is an average clearance of 0.26mL/kg/h.

Elimination Route

Monoclonal antibodies are not eliminated in the urine, and only a small amount is excreted in bile. Most monoclonal antibodies are catabolized in lysosomes to amino acids.